Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and…

Overview of attention for article published in The Journal of Headache and Pain, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 60 Dimensions

Readers on

mendeley: 102 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

galcanezumab

Cited by Canadian Agency for Drugs and Technologies in Health on 28 Feb 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.